A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Makoto Kawaguchi; Keiichi Ito; Hideyuki Shimazaki; Tomohiko Asano

doi:10.1016/j.eucr.2017.07.002

A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Urol Case Rep. 2017 Sep 8:15:14-16. doi: 10.1016/j.eucr.2017.07.002. eCollection 2017 Nov.

Authors

Makoto Kawaguchi¹, Keiichi Ito¹, Hideyuki Shimazaki², Tomohiko Asano¹

Affiliations

¹ Department of Urology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
² Department of Laboratory Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.

Abstract

The present case underwent right laparoscopic radical nephrectomy for collecting duct carcinoma (CDC). Recurrence occurred in the lung and the bone (skull and lumber vertebra) in 2011. Gemcitabine plus cisplatin (GC) chemotherapy and monthly zoledronic acid (ZA) was then started. The massive skull bone metastases were prominently reossified after several courses of the therapy. The patient received 16 courses of GC chemotherapy and monthly ZA, and pulmonary metastases and reossified skull bone metastases were stable for 23 months. Although we cannot verify the adoptive effect of ZA on the reossification, this combination may be effective for CDC bone metastases.

Keywords: Bone metastasis; Chemotherapy; Collecting duct carcinoma; Zoledronic acid.

Publication types

Case Reports